<?xml version="1.0" encoding="UTF-8"?>
<p>The prevalence of metabolic syndrome (MetS), a cluster of interrelated metabolic disorders, has been on the rise globally. The International Diabetes Federation estimated that 25% of the global adult population has MetS, and its prevalence is predicted to increase in the next few decades [
 <xref rid="B1-molecules-25-02669" ref-type="bibr">1</xref>]. The rise in the prevalence of MetS poses a serious public health burden, especially in resource-limited countries in sub-Saharan Africa [
 <xref rid="B2-molecules-25-02669" ref-type="bibr">2</xref>]. Several billions of dollars have already been spent by governments in developing countries to curb the widespread effects of MetS and associated risk factors [
 <xref rid="B3-molecules-25-02669" ref-type="bibr">3</xref>].
</p>
